<svg xmlns="http://www.w3.org/2000/svg" width="550" height="5110" viewBox="0 0 550 5110">
  <defs>
    <style>
      .cls-1 {
        fill: none;
        stroke: #000;
        stroke-width: 1px;
      }

      .cls-2, .cls-4, .cls-7 {
        font-size: 19.726px;
        font-family: "Myriad Pro";
      }

      .cls-3 {
        fill: #5261ac;
      }

      .cls-3, .cls-7, .cls-8 {
        font-weight: 700;
      }

      .cls-5 {
        font-size: 9.863px;
        font-family: Arial;
      }

      .cls-6 {
        fill: #5262ad;
      }

      .cls-9 {
        font-size: 18.411px;
      }

      .cls-10, .cls-9 {
        font-weight: 600;
      }
    </style>
  </defs>
  <rect id="box" class="cls-1" y="808" width="538" height="617"/>
  <text id="_INDICATION_OPSUMIT_is_an_endothelin_receptor_antagonist_ERA_" data-name=" INDICATION OPSUMIT is an endothelin receptor  antagonist (ERA)" class="cls-2" transform="translate(-0.496 17.077) scale(1.52 1.521)"><tspan class="cls-3">INDICATION</tspan><tspan x="0" dy="23.672">OPSUMIT is an endothelin receptor </tspan><tspan x="0" dy="23.672">antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, </tspan><tspan x="0" dy="23.672">initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH </tspan><tspan x="0" dy="23.672">(decreased 6-OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced </tspan><tspan x="0" dy="23.672">hospitalization for PAH. </tspan><tspan x="0" dy="23.672"></tspan><tspan x="0" dy="23.672">Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. Patients were </tspan><tspan x="0" dy="23.672">treated with OPSUMIT monotherapy or in combination with phosphodiesterase-5 </tspan><tspan x="0" dy="23.672">inhibitors or inhaled prostanoids. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).</tspan><tspan class="cls-3" x="0" dy="47.343">IMPORTANT SAFETY INFORMATION</tspan><tspan class="cls-3" x="0" dy="23.672"></tspan><tspan class="cls-3" x="0" dy="23.672">BOXED WARNING: </tspan><tspan class="cls-3" x="0" dy="23.672">EMBRYO-FETAL TOXICITYBOXED WARNING: EMBRYO-FETAL TOXICITY</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-7">Do not administer OPSUMIT to a </tspan></tspan><tspan class="cls-8" x="0" dy="23.672">pregnant female because it may</tspan><tspan class="cls-8" x="0" dy="23.672">cause fetal harm.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-7">Females of reproductive potential: </tspan></tspan><tspan class="cls-8" x="0" dy="23.672">Exclude pregnancy before the start </tspan><tspan class="cls-8" x="0" dy="23.672">of treatment, monthly during </tspan><tspan class="cls-8" x="0" dy="23.672">treatment, and 1 month after </tspan><tspan class="cls-8" x="0" dy="23.672">stopping treatment. Prevent </tspan><tspan class="cls-8" x="0" dy="23.672">pregnancy during treatment and for </tspan><tspan class="cls-8" x="0" dy="23.672">one month after stopping treatment </tspan><tspan class="cls-8" x="0" dy="23.672">by using acceptable methods of </tspan><tspan class="cls-8" x="0" dy="23.672">contraception. </tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-7">For all female patients, OPSUMIT is </tspan></tspan><tspan class="cls-8" x="0" dy="23.672">available only through a restricted </tspan><tspan class="cls-8" x="0" dy="23.672">program called the  OPSUMIT Risk  </tspan><tspan class="cls-8" x="0" dy="23.672">Evaluation and Mitigation Strategy </tspan><tspan class="cls-8" x="0" dy="23.672">(REMS).</tspan><tspan class="cls-3" x="0" dy="47.343">CONTRAINDICATIONS</tspan><tspan x="0" dy="23.672">Pregnancy: OPSUMIT may cause fetal harm when administered to a pregnant woman. OPSUMIT is contraindicated in females who are pregnant. If OPSUMIT is used during </tspan><tspan x="0" dy="23.672">pregnancy, apprise the patient of the </tspan><tspan x="0" dy="23.672">potential hazard to a fetus.</tspan><tspan x="0" dy="23.672"></tspan><tspan class="cls-3" x="0" dy="23.672">WARNINGS AND PRECAUTIONS</tspan><tspan class="cls-3" x="0" dy="23.672">Embryo-fetal Toxicity and </tspan><tspan class="cls-3" x="0" dy="23.672">OPSUMIT REMS Program<tspan class="cls-9">  </tspan></tspan><tspan x="0" dy="23.672">Due to the risk of embryo-fetal toxicity, </tspan><tspan x="0" dy="23.672">OPSUMIT is available for females only through a restricted program called the OPSUMIT REMS Program. For females of reproductive potential, exclude pregnancy prior to </tspan><tspan x="0" dy="23.672">initiation of therapy, ensure use of acceptable contraceptive methods, and obtain monthly pregnancy tests.</tspan><tspan x="0" dy="23.672"></tspan><tspan x="0" dy="23.672">Notable requirements of the OPSUMIT REMS Program include:</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Prescribers must be certified with the </tspan></tspan><tspan x="0" dy="23.672">program by enrolling and completing </tspan><tspan x="0" dy="23.672">training.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">All females, regardless of reproductive </tspan></tspan><tspan x="0" dy="23.672">potential, must enroll in the OPSUMIT     </tspan><tspan x="0" dy="23.672">REMS Program prior to initiating OPSUMIT.         </tspan><tspan x="0" dy="23.672">Male patients are not enrolled in the REMS.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Females of reproductive potential must      </tspan></tspan><tspan x="0" dy="23.672">comply with the pregnancy testing and </tspan><tspan x="0" dy="23.672">contraception requirements.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Pharmacies must be certified with the </tspan></tspan><tspan x="0" dy="23.672">program and must only dispense to </tspan><tspan x="0" dy="23.672">patients who are authorized to receive </tspan><tspan x="0" dy="23.672">OPSUMIT.</tspan><tspan x="0" dy="23.672"></tspan><tspan class="cls-3" x="0" dy="23.672">Hepatotoxicity<tspan class="cls-10"> </tspan></tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Other ERAs have caused elevations of</tspan></tspan><tspan x="0" dy="23.672">aminotransferases, hepatotoxicity, and liver failure. The incidence of elevated </tspan><tspan x="0" dy="23.672">aminotransferases in the SERAPHIN study </tspan><tspan x="0" dy="23.672">&gt;3 × ULN was 3.4% for OPSUMIT vs 4.5% </tspan><tspan x="0" dy="23.672">for placebo, and &gt;8 × ULN was 2.1% vs </tspan><tspan x="0" dy="23.672">0.4%, respectively. Discontinuations for </tspan><tspan x="0" dy="23.672">hepatic adverse events were 3.3% for </tspan><tspan x="0" dy="23.672">OPSUMIT vs 1.6% for placebo.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Obtain liver enzyme tests prior to </tspan></tspan><tspan x="0" dy="23.672">initiation of OPSUMIT and repeat during     </tspan><tspan x="0" dy="23.672">treatment as clinically indicated.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Advise patients to report symptoms </tspan></tspan><tspan x="0" dy="23.672">suggesting hepatic injury (nausea, </tspan><tspan x="0" dy="23.672">vomiting, right upper quadrant pain, </tspan><tspan x="0" dy="23.672">fatigue, anorexia, jaundice, dark urine,     </tspan><tspan x="0" dy="23.672">fever, or itching).</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">If clinically relevant aminotransferase </tspan></tspan><tspan x="0" dy="23.672">elevations occur, or if elevations are </tspan><tspan x="0" dy="23.672">accompanied by an increase in bilirubin </tspan><tspan x="0" dy="23.672">&gt;2 × ULN, or by clinical symptoms of </tspan><tspan x="0" dy="23.672">hepatotoxicity, discontinue OPSUMIT.</tspan><tspan x="0" dy="23.672">Consider re-initiation of OPSUMIT when </tspan><tspan x="0" dy="23.672">hepatic enzyme levels normalize in </tspan><tspan x="0" dy="23.672">patients who have not experienced clinical     </tspan><tspan x="0" dy="23.672">symptoms of hepatotoxicity.</tspan><tspan class="cls-3" x="0" dy="47.343">Hemoglobin Decrease </tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Decreases in hemoglobin concentration                 </tspan></tspan><tspan x="0" dy="23.672">and hematocrit have occurred following     </tspan><tspan x="0" dy="23.672">administration of other ERAs and in clinical </tspan><tspan x="0" dy="23.672">studies with OPSUMIT. These decreases </tspan><tspan x="0" dy="23.672">occurred early and stabilized thereafter.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">In the SERAPHIN study, OPSUMIT caused a      </tspan></tspan><tspan x="0" dy="23.672">mean decrease in hemoglobin (from </tspan><tspan x="0" dy="23.672">baseline to 18 months) of about 1.0 g/dL     </tspan><tspan x="0" dy="23.672">vs no change in the placebo group. A </tspan><tspan x="0" dy="23.672">decrease in hemoglobin to below 10.0     </tspan><tspan x="0" dy="23.672">g/dL was reported in 8.7% of the OPSUMIT </tspan><tspan x="0" dy="23.672">group vs 3.4% for placebo. Decreases in</tspan><tspan x="0" dy="23.672">hemoglobin seldom require transfusion.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Initiation of OPSUMIT is not </tspan></tspan><tspan x="0" dy="23.672">recommended in patients with severe anemia. Measure hemoglobin prior to</tspan><tspan x="0" dy="23.672">initiation of treatment and repeat during treatment as clinically indicated.</tspan><tspan class="cls-3" x="0" dy="23.672">Pulmonary Edema with Pulmonary </tspan><tspan class="cls-3" x="0" dy="23.672">Veno-occlusive Disease (PVOD)</tspan><tspan x="0" dy="23.672">Should signs of pulmonary edema occur, </tspan><tspan x="0" dy="23.672">consider the possibility of associated PVOD. </tspan><tspan x="0" dy="23.672">If confirmed, discontinue OPSUMIT.</tspan><tspan x="0" dy="23.672"></tspan><tspan class="cls-3" x="0" dy="23.672">Decreased Sperm Counts</tspan><tspan x="0" dy="23.672">Other ERAs have caused adverse effects on spermatogenesis. Counsel men about </tspan><tspan x="0" dy="23.672">potential effects on fertility.</tspan><tspan x="0" dy="23.672"></tspan><tspan class="cls-3" x="0" dy="23.672">ADVERSE REACTIONS</tspan><tspan x="0" dy="23.672">Most common adverse reactions (more</tspan><tspan x="0" dy="23.672">frequent than placebo by ≥3%) were anemia (13% vs 3%), nasopharyngitis/pharyngitis (20% vs 13%), bronchitis (12% vs 6%), </tspan><tspan x="0" dy="23.672">headache (14% vs 9%), influenza (6% vs 2%), and urinary tract infection (9% vs 6%).</tspan><tspan x="0" dy="23.672"></tspan><tspan class="cls-3" x="0" dy="23.672">DRUG INTERACTIONS</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Strong inducers of CYP3A4 such as </tspan></tspan><tspan x="0" dy="23.672">rifampin significantly reduce macitentan     </tspan><tspan x="0" dy="23.672">exposure. Concomitant use of OPSUMIT </tspan><tspan x="0" dy="23.672">with strong CYP3A4 inducers should be </tspan><tspan x="0" dy="23.672">avoided.</tspan><tspan class="cls-5" x="0" dy="23.672"><tspan class="cls-6">■   </tspan><tspan class="cls-4">Strong inhibitors of CYP3A4 like </tspan></tspan><tspan x="0" dy="23.672">ketoconazole approximately double </tspan><tspan x="0" dy="23.672">macitentan exposure. Many HIV drugs like     </tspan><tspan x="0" dy="23.672">ritonavir are strong inhibitors of CYP3A4. </tspan><tspan x="0" dy="23.672">Avoid concomitant use of OPSUMIT with </tspan><tspan x="0" dy="23.672">strong CYP3A4 inhibitors. Use other PAH </tspan><tspan x="0" dy="23.672">treatment options when strong CYP3A4 </tspan><tspan x="0" dy="23.672">inhibitors are needed as part of HIV </tspan><tspan x="0" dy="23.672">treatment.</tspan></text>
</svg>
